Anti-TNF-α therapy in childhood pustular psoriasis [1]

Dermatology

Volumn 213, Issue 4, 2006, Pages 350-352

  Pereira, Teresa M ^a   Vieira, Ana Paula ^a   Fernandes, José Carlos ^a   Antunes, Henedina ^a   Basto, A Sousa ^a  

^a HOSPITAL DE BRAGA   (Portugal)

Author keywords

Childhood pustular psoriasis; Etanercept; Infliximab; Methotrexate

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; CYCLOSPORIN A; ETANERCEPT; ETRETIN; INFLIXIMAB; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CASE REPORT; CHILDHOOD DISEASE; DISEASE EXACERBATION; FEMALE; HUMAN; IMMUNOTHERAPY; LETTER; PRESCHOOL CHILD; PRIORITY JOURNAL; PSORIASIS; SYSTEMIC THERAPY;

ANTIBODIES, MONOCLONAL; CHILD, PRESCHOOL; CYCLOSPORINE; DERMATOLOGIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33751524052     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096202     Document Type: Letter

References (17)

1. Zelickson BD, Muller SA: Generalized pustular psoriasis in childhood. J Am Acad Dermatol 1991;24:186-194.
2. Hogan PA: Papulosquamous disease; in Lawrence A, Schachner R, Hansen C (eds): Pediatric Dermatology, ed 3. New York, Churchill Livingstone, 2003, pp 643-682.
3. Elewski BE: Infliximab for the treatment of severe pustular psoriasis. J Am Acad Dermatol 2002;47:796-797.
4. Lisby S, Gniadecki R: Infliximab (Remicade®) for acute, severe pustular and erytrodermic psoriasis. Acta Derm Venereol 2004;84:247-248.
5. Newland MR, Weinstein A, Kerdel F: Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int J Dermatol 2002;41:449-452.
6. Al-Salem IH: Striking and rapid improvement of plaque psoriasis with infliximab. Dermatology 2003;207:54-56.
7. Menter A, Cush J: Successful treatment of pediatric psoriasis with infliximab. Pediatr Dermatol 2004;1:87-88.
8. Thielen AM, Kuenzli J, Saurat JH: Cutaneous adverse events of biological therapy for psoriasis: review of the literature. Dermatology 2005;211:209-217.
9. Winterfield L, Menter A: Psoriasis and its treatment with infliximab-mediated tumor necrosis factor-α blockade. Dermatol Clin 2002;22:437-447.
10. Barland C, Kerdel F: Addition of low-dose methotrexate to infliximab in the treatment of a patient with severe, recalcitrant pustular psoriasis. Arch Dermatol 2003;139:949-950.
11. Thurber M, Feasel A, Strochlein J, Hymes MR: Pustular psoriasis induced by infliximab. J Drugs Dermatol 2004;3:439-440.
12. Exadakylos P, Reiss T, Schobess R: Acute hepatotoxicity with intermediate-dose methotrexate in children with leukaemia and non-Hodkin's lymphoma. Klin Pädiatr 1994;206:315-318.
13. Zachariae H: Have methotrexate-induced liver fibrosis and cirrhosis become rare. Dermatology 2005;211:307-308.
14. Li SP, Tang WYM, Lam WY, Wong SN: Renal failure and cholestatic jaundice as unusual complications of childhood pustular psoriasis. Br J Dermatol 2000;143:1292-1296.
15. Strober BE: Successful treatment of psoriasis and psoriatic arthritis with etanercept and methotrexate in a patient newly unresponsive to infliximab. Arch Dermatol 2004;140:366.
16. Kamarashev J, Lor P, Forster A, Heinzeerling L, Burg G, Nesle FO: Generalized pustular psoriasis induced by cyclosporine a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept. Dermatology 2002;205:213-216.
17. Lovell DJ, Gianini EH, Reiff A, Jones OY, Schneider R, et al: Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2003;48:218-226.